Detalhe da pesquisa
1.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Blood
; 138(21): 2031-2041, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407542
2.
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Blood
; 134(23): 2036-2045, 2019 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31511239
3.
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
Leukemia
; 37(5): 1060-1067, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37069326
4.
Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
Cancer Med
; 12(3): 2990-2998, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36168187
5.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Leukemia
; 37(3): 617-626, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36717654
6.
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
J Clin Pharmacol
; 61(11): 1454-1465, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34115385
7.
A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.
Blood Adv
; 5(14): 2925-2934, 2021 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34309636
8.
Effect of femoral head size on metal-on-HXLPE hip arthroplasty outcome in a combined analysis of six national and regional registries.
J Bone Joint Surg Am
; 96 Suppl 1: 12-8, 2014 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25520414